Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alector Inc
(NQ:
ALEC
)
5.310
+0.240 (+4.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alector Inc
< Previous
1
2
3
4
5
Next >
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
July 31, 2024
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
July 23, 2024
From
Alector, Inc.
Via
GlobeNewswire
Recap: Alector Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024
From
Alector, Inc.
Via
GlobeNewswire
Perion Network Cuts Revenue Outlook, Joins Skye Bioscience And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 10, 2024
Via
Benzinga
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
June 10, 2024
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
From
Alector, Inc.
Via
GlobeNewswire
Earnings Outlook For Alector
February 26, 2024
Via
Benzinga
Why Alector (ALEC) Stock Is Diving Today
January 17, 2024
Alector shares are trading lower by 14.9% during Wednesday's session. The company announced the pricing of a $75 million public offering.
Via
Benzinga
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
May 09, 2024
From
Alector, Inc.
Via
GlobeNewswire
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Alector, Inc.
Via
GlobeNewswire
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 06, 2024
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Via
InvestorPlace
Alector to Participate in Upcoming Healthcare Conferences
February 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
February 20, 2024
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 08, 2024
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
From
Alector, Inc.
Via
GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
January 23, 2024
These three companies are developing treatments for brain diseases that have a great deal of potential, making them top neuroscience stocks.
Via
InvestorPlace
Alector Announces Closing of Public Offering
January 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
SolarEdge Technologies, Calavo Growers, Fisker And Other Big Stocks Moving Lower On Wednesday
January 17, 2024
U.S. stocks traded lower, with the Nasdaq Composite falling more than 150 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Alector Announces Pricing of Public Offering of Common Stock
January 17, 2024
From
Alector, Inc.
Via
GlobeNewswire
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 17, 2024
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 16, 2024
Via
Benzinga
Alector Announces Proposed Public Offering of Common Stock
January 16, 2024
From
Alector, Inc.
Via
GlobeNewswire
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.